Drug intelligence / Profile preview

GRT3938Y

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

GRT3938Y is an investigational central analgesic drug studied for the treatment of painful diabetic peripheral neuropathy. It has been evaluated in randomized, placebo-controlled clinical trials to assess its efficacy and safety in reducing pain associated with this condition. The specific mechanism of action, molecular target, and chemical class have not been disclosed in public sources as of June 2025. The drug is administered orally as overencapsulated tablets[1][3].

Other names: GRT3938YGRT-3938YGRT 3938Y

Beyond the preview

Go deeper on GRT3938Y.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRT3938Y.

Explore the full profile